Relmada Therapeutics and PyroGenesis Secure Capital Through Private Placements
Key Facts
Relmada Therapeutics (RLMD) has successfully announced an oversubscribed $160.0 million private investment in public equity (PIPE) financing. The financing round attracted significant interest from top-tier institutional investors, including Venrock Healthcare Capital Partners, Janus Henderson Investors, and RA Capital Management. These funds are earmarked to advance Relmada's clinical-stage therapies targeting oncology and central nervous system (CNS) indications. Simultaneously, PyroGenesis (PYR) disclosed its intention to complete a non-brokered private placement to raise up to $1,000,000. The PyroGenesis offering is priced at $0.54 per unit and aims to provide necessary liquidity for its plasma-based technology operations. The strong institutional backing for Relmada highlights market confidence in its development pipeline, while PyroGenesis secures capital for industrial growth.
Get AI-powered deep analysis for every story with a paid subscription
Upgrade for Analysis